Northwest Investment Counselors’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
$149K Buy
+1,295
New +$147K 0.03% 165
2024
Q2
Sell
-485
Closed -$46.9K 388
2024
Q1
$46.9K Buy
+485
New +$49.7K 0.01% 242
2023
Q4
Sell
-354
Closed -$36.1K 402
2023
Q3
$36.1K Buy
354
+50
+16% +$5.08K 0.01% 259
2023
Q2
$30.7K Buy
304
+42
+16% +$4.2K 0.01% 280
2023
Q1
$24.1K Hold
262
0.01% 310
2022
Q4
$23.8K Hold
262
0.01% 317
2022
Q3
$20K Hold
262
0.01% 304
2022
Q2
$22K Hold
262
0.01% 293
2022
Q1
$23K Hold
262
0.01% 304
2021
Q4
$23K Buy
+262
New +$21.8K 0.01% 296
2021
Q2
Sell
-484
Closed -$41K 338
2021
Q1
$41K Buy
+484
New +$43.4K 0.01% 240
2020
Q4
Sell
-375
Closed -$33K 335
2020
Q3
$33K Buy
+375
New +$32.5K 0.01% 230
2019
Q4
Sell
-75
Closed -$7K 386
2019
Q3
$7K Buy
+75
New +$6.73K ﹤0.01% 400
2017
Q4
Sell
-738
Closed -$57K 246
2017
Q3
$57K Buy
738
+654
+779% +$49.4K 0.02% 174
2017
Q2
$6K Buy
+84
New +$5.95K ﹤0.01% 279

Other funds holding NVS

Northwest Investment Counselors's NVS Position: Q3 2024 in Review

Northwest Investment Counselors opened a new position in Novartis (NVS) in Q3 2024: 1,295 shares worth $149K. The stake represents 0.03% of the portfolio and ranks #165 among its holdings. This is a return to the name: Northwest Investment Counselors previously reported a position in NVS as recently as Q1 2024.

Northwest Investment Counselors first reported a position in NVS in Q2 2017 and has held it in 15 quarters since. 1,312 funds tracked by Wall St. Rank hold NVS as of Q3 2024.

  • Northwest Investment Counselors held 1,295 shares of Novartis worth $149K as of Q3 2024.
  • Novartis was a new Northwest Investment Counselors position in Q3 2024.
  • Novartis made up 0.03% of Northwest Investment Counselors's portfolio in Q3 2024, its #165 holding.
  • Northwest Investment Counselors first reported a position in Novartis in Q2 2017 and has held it in 15 quarters since.
  • 1,312 funds tracked by Wall St. Rank held Novartis as of Q3 2024.

Based on Northwest Investment Counselors's 13F filing for Q3 2024, filed 21 Oct 2024.